CNXU (Conexeu Sciences) Asset Turnover: 0.00 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNXU Conexeu Sciences Inc CNXU
12 GF Score
Price $7.25
! 1 Warning Sign
View Full Analysis

What is Conexeu Sciences Asset Turnover?

Conexeu Sciences CNXU -9.91% 12 Asset Turnover is 0.00 as of Apr. 2026. GuruFocus rates CNXU with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Conexeu Sciences's Revenue for the three months ended in Apr. 2026 was $0.00 Mil. Conexeu Sciences's Total Assets for the quarter that ended in Apr. 2026 was $7.95 Mil. Therefore, Conexeu Sciences's Asset Turnover for the quarter that ended in Apr. 2026 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Conexeu Sciences's annualized ROE % for the quarter that ended in Apr. 2026 was -131.45%. It is also linked to ROA % through Du Pont Formula. Conexeu Sciences's annualized ROA % for the quarter that ended in Apr. 2026 was -115.90%.


Conexeu Sciences  (NAS:CNXU) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Conexeu Sciences's annulized ROE % for the quarter that ended in Apr. 2026 is

ROE %**(Q: Apr. 2026 )
=Net Income/Total Stockholders Equity
=-9.216/7.011
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-9.216 / 0)*(0 / 7.9515)*(7.9515/ 7.011)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.1341
=ROA %*Equity Multiplier
=-115.90 %*1.1341
=-131.45 %

Note: The Net Income data used here is four times the quarterly (Apr. 2026) net income data. The Revenue data used here is four times the quarterly (Apr. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Conexeu Sciences's annulized ROA % for the quarter that ended in Apr. 2026 is

ROA %(Q: Apr. 2026 )
=Net Income/Total Assets
=-9.216/7.9515
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-9.216 / 0)*(0 / 7.9515)
=Net Margin %*Asset Turnover
= %*0
=-115.90 %

Note: The Net Income data used here is four times the quarterly (Apr. 2026) net income data. The Revenue data used here is four times the quarterly (Apr. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Conexeu Sciences Asset Turnover Related Terms


Conexeu Sciences Asset Turnover Historical Data

* Premium members only.

The historical data trend for Conexeu Sciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Conexeu Sciences Asset Turnover Chart

Conexeu Sciences Annual Data
Trend Oct24 Oct25
Asset Turnover
0.00 0.00

Conexeu Sciences Quarterly Data
Oct24 Jan25 Apr25 Oct25 Jan26 Apr26
Asset Turnover Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

CNXU vs GALT, SRZN, RNAC: Asset Turnover Comparison

For the Biotechnology subindustry, Conexeu Sciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conexeu Sciences Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conexeu Sciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Conexeu Sciences's Asset Turnover falls into.


CNXU
12GF Score
Conexeu Sciences Inc CNXU
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Conexeu Sciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Conexeu Sciences's Asset Turnover for the fiscal year that ended in Oct. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Oct. 2025 )/( (Total Assets (A: Oct. 2024 )+Total Assets (A: Oct. 2025 ))/ count )
=0/( (0.534+7.689)/ 2 )
=0/4.1115
=0.00

Conexeu Sciences's Asset Turnover for the quarter that ended in Apr. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Apr. 2026 )/( (Total Assets (Q: Jan. 2026 )+Total Assets (Q: Apr. 2026 ))/ count )
=0/( (7.703+8.2)/ 2 )
=0/7.9515
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.00 mean?
Conexeu Sciences (CNXU) has a Asset Turnover of 0.00 as of Apr. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Conexeu Sciences and its competitors.
Is Conexeu Sciences' Asset Turnover too high?
Conexeu Sciences' current Asset Turnover is 0.00. Overall, Conexeu Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Conexeu Sciences' Asset Turnover compare to GALT and SRZN?
Conexeu Sciences' Asset Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Conexeu Sciences and its competitors. Conexeu Sciences's current Asset Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Conexeu Sciences stock overvalued right now?
Conexeu Sciences (CNXU) has a current Asset Turnover of 0.00. The current Asset Turnover is 0.00. Conexeu Sciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Conexeu Sciences (CNXU), the current Asset Turnover is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Conexeu Sciences Business Description

Address 50 West Liberty Street, Suite 880, Reno, NV, USA, 89501
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
12GF Score

Get the complete analysis for CNXU

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.25
Price